Cryptocol

FDA Approval "coming soon"

Giá lên
OTC:VDRM   ViaDerma, Inc.
From a post on ihub- an investor emailed investor relations and received this response $$$

to: info@viadermalicensing.com
cc: sales@viadermalicensing.com

subject: Update
mailed-by: gmail.com


Hello,
I have a few questions:

1-Can we expect a PR with a FDA approval this week or next for your product for treating Premature Ejaculation?

2-Are sales rolling out this quarter for Viabecline?

3-Will the lawsuit be dropped or settled this quarter? Will ViaDerma prevail?

4-Hasn't the efficacy already been done for Viabecline? Why have you started a new independent study in Texas to prove Viabecline's efficacy in treating diabetic foot wounds?

5-How much revenue do you expect from the grass roots THC and non-THC Cannabinoids, both in a patch form, roll on and spray signed with the Canadian company? Are your plans to sell licensing agreements to major producers?

Thank you

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~



info@viadermalicensing.com

3:08 PM (17 hours ago)



FDA approval is on track. No delays are expected. Stand by for updates on that


Rollout is also still on time and should be out by the of the quarter (one month from now)


We received a continuance to submit our reply to the lawsuit. That's usually pretty standard. We will report developments as they happen but we feel very strongly we will prevail. We cant say too much until after we file our official reply with the court


Efficacy has been done but the reason for the independent study is to show we do it better.


Can't answer any revenue guidance question yet until we release that to the public. Hopefully soon. Stay tuned for more news in the near future. We expect to report on some of these and other developments shortly.


Thanks



Investor Relations

(310) 734 6111

Thông báo miễn trừ trách nhiệm

Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.